Similar Items: Impact of Targeted Immune Checkpoint Inhibitor Adjuvant Therapy on Recurrence-Free Survival and Functional Recovery in Stage III Tongue Cancer Patients: A Retrospective Cohort Study
- Real‐World Survival Over 25 Years in Extensive‐Stage Small‐Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors
- A Novel Prognostic Model Based on Prognostic Nutritional Index and Systemic Immune-Inflammation Index for Cancer Patients Treated with Immune Checkpoint Inhibitors
- The Prognostic Value of Serum Inflammatory Markers in Nasopharyngeal Carcinoma Patients Treated With Immune Checkpoint Inhibitors: A Multicenter Study
- Efficacy and Safety of Regorafenib with or without Immune Checkpoint Inhibitors as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Systematic Review and Arm-Level Synthesis of Real-World Comparative Cohorts
- Immune‐Related Adverse Events and Therapeutic Outcomes After Stopping Immune Checkpoint Inhibitors due to Toxicity Among Patients With Metastatic Melanoma (University Hospitals Sussex)
- Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune Checkpoint Inhibitors in High-Risk Non-muscle-Invasive Bladder Cancer